Patel Naimish 4
4 · CRISPR Therapeutics AG · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
CRISPR (CRSP) CMO Naimish Patel Sells 3,150 Shares
What Happened
Naimish Patel, Chief Medical Officer of CRISPR Therapeutics (CRSP), had 8,125 restricted stock units convert/vest on March 14, 2026 (reported as a derivative exercise/conversion). Following the vesting, Patel sold 3,150 shares in an open-market sale on March 16, 2026 at $48.26 per share, receiving $152,019. The sale was done to satisfy tax withholding tied to the RSU vesting and was mandated by the company's RSU Settlement Policy (not a discretionary trade).
Key Details
- Transactions reported:
- 2026-03-14: Conversion/exercise of derivative (RSU vesting) — 8,125 shares (no cash price; conversion event).
- 2026-03-16: Open-market sale — 3,150 shares @ $48.26 = $152,019.
- 2026-03-14: A derivative disposition of 8,125 shares is also reported (reflecting the conversion/settlement mechanics).
- Shares owned after transaction: Not specified in the filing.
- Relevant footnotes:
- F4: The 3,150-share sale represents shares sold to cover tax withholding for the RSU vesting and was required by company policy (not a discretionary sale).
- F5: The RSU award (32,500 shares) was granted 3/14/2025 with quarterly vesting; 8,125 shares vested 3/14/2026.
- F1: Some shares remain subject to a lock-up agreement with the underwriters of the issuer’s convertible senior notes offering.
- F2/F3: RSUs convert to one common share each; the reporting includes 592 shares from the employee stock purchase plan.
- Filing date / timeliness: Form 4 filed 2026-03-17 covering the 3/14–3/16 activity; no late-filing flag was indicated.
Context
- The March 14 entry is a vesting/conversion of RSUs (transaction code M for exercise/conversion of a derivative). A portion of the vested shares was sold shortly after to cover taxes—this is a routine, non-discretionary settlement-related sale rather than a voluntary sell signal from the insider.
- For retail investors, mandatory withholding sales tied to RSU vesting are common and generally less informative about insider sentiment than voluntary open-market purchases.
Insider Transaction Report
Form 4
Patel Naimish
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Shares
[F1][F2][F3]2026-03-14+8,125→ 16,293 total - Sale
Common Shares
[F4]2026-03-16$48.26/sh−3,150$152,019→ 13,143 total - Exercise/Conversion
Restricted Stock Units
[F2][F1][F5]2026-03-14−8,125→ 24,375 total→ Common Shares (8,125 underlying)
Footnotes (5)
- [F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]Includes 592 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
- [F4]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F5]This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.
Signature
Elizabeth Ryland Waldinger, attorney-in-fact|2026-03-17